Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma

Terasawa, Hiroyuki; Kinugasa, Hideaki; Ako, Soichiro; Hirai, Maiko; Matsushita, Hiroshi; Uchida, Daisuke; Tomoda, Takeshi; Matsumoto, Kazuyuki; Horiguchi, Shigeru; Kato, Hironari; Nouso, Kazuhiro; Okada, Hiroyuki

doi:10.1080/15384047.2019.1638685

Cited by 17 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early ctDNA increase during chemotherapy seems to be relevant to assess early treatment efficacy, but needs further validation as studies were conducted in a very limited number of patients. Finally, less invasive procedures could even be developed in the future, as Terasawa et al 86 recently found similar KRAS mut detection rates in plasma and urine. To conclude, ctDNA is a promising biomarker for PA management.…”

Section: Discussionmentioning

confidence: 99%

Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review

Abdallah

Taly

Zhao

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

Background:While no biomarker is currently recommended for the management of pancreatic adnocarcinoma (PA) Circulating tumor DNA (ctDNA) seems promising but little is known on how it may help to manage our patients in the near future. Materials and methods:This systematic review of literature was designed to explore the current knowledge on ctDNA as a screening, diagnostic, prognostic, predictive and theranostic biomarker in the management of PA. Results:We retrieved 82 publications, including 62 full-text articles, 3 meta-analyses, 2 clinical trials and 1 abstract. The results were categorized into sections about screening, diagnosis; prognosis and follow-up of localized and advanced PA together with possible theranostics applications. Although its specificity is excellent, the current sensitivity of ctDNA remains a limitation especially in patients without metastatic disease. Therefore, this biomarker cannot be currently used as a screening or diagnostic tool. Increasing evidence suggests that ctDNA is a relevant candidate biomarker to assess minimal residual disease after radical surgery, but also a strong independent biomarker linked to a poor prognosis in advanced PA. Some recent data also indicates that ctDNA is an attractive biomarker for longitudinal follow-up and possibly early treatment adaptation. Its role in tumor profiling in advanced disease to decide targeted treatments remains to be explored. Conclusion:CtDNA appears to be a reliable prognostic tool. Though romising results have been reported, further studies are needed to define exactly how ctDNA can help physicians in the screening, diagnosis and treatment, as PA is expected to become a major cause of cancer-related deaths in the forthcoming decade.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review

Abdallah

Taly

Zhao

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…To date, the "gold standard" for OSCC diagnosis is still a clinical oral examination integrated by a histopathological examination on the biopsy of suspicious lesions [33]. However, cancer research focuses on finding less invasive and more effective methods to make an early diagnosis, monitor its evolution and therapeutic response [34][35][36][37][38][39][40][41][42][43]. For example, cervical scraping has been commonly used to screen for cervical cancer in clinical examination [36,37].…”

Section: Discussionmentioning

confidence: 99%

Identification of RNA-splicing factor Lsm12 as a novel tumor-associated gene and a potent biomarker in Oral Squamous Cell Carcinoma (OSCC)

Yan

Xue

Zhang

et al. 2022

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Oral squamous cell carcinoma (OSCC) is one of the common cancers worldwide. The lack of specific biomarkers and therapeutic targets leads to delayed diagnosis and hence the poor prognosis of OSCC patients. Thus, it is urgent to identify effective biomarkers and therapeutic targets for OSCC. Methods We established the golden hamster carcinogenic model of OSCC induced by 7,12-dimethylbenz(a) anthrancene (DMBA) and used mRNA microarrays to detect the differentially expressed genes (DEGs). DEGs were validated in OSCC clinical tissue microarrays using immunohistochemistry method. Whole transcriptome sequencing was performed to obtain an overview of biological functions of Lsm12. PCR assay and sequencing were employed to investigate the alternative splicing of genes regulated by Lsm12. Cell proliferation, colony formation, Transwell migration and invasion assay and in vivo tumor formation assay were performed to investigate the roles of Lsm12 and two transcript variants of USO1 in OSCC cells. Results Lsm12 was identified to be significantly up-regulated in the animal model of OSCC tumorigenesis, which was validated in the clinical OSCC samples. In the paired normal tissues, Lsm12 staining was negative (91%, 92/101) or weak, while in OSCC tissues, positive rate is 100% and strong staining spread over the whole tissues in 93 (93/101, 92%) cases. Lsm12 overexpression significantly promoted OSCC cell growth, colony formation, migration and invasion abilities, while Lsm12 knockdown showed the opposite trends on these phenotypes and obviously inhibited the tumor formation in vivo. Furthermore, Lsm12 overexpression caused the inclusion of USO1 exon 15 and Lsm12 knockdown induced exon 15 skipping. Exon 15-retained USO1 significantly promoted the malignant phenotypes of OSCC cells when compared with the exon 15-deleted USO1. Conclusions We identified Lsm12, a novel tumorigenesis-related gene, as an important regulator involved in OSCC tumorigenesis. Lsm12 is a novel RNA-splicing related gene and can regulate the alternative splicing of USO1 exon 15 which was associated closely with OSCC carcinogenesis. Our findings thus provide that Lsm12 might be a potent biomarker and potential therapeutic target for OSCC.

show abstract

“…The TR-ctDNA research field has continued to expand to encompass other types of cancer, including the demonstration of TR-ctDNA detection in patients with breast cancer ( Liu and Liu 2018 ; Guan et al 2020 ; J. Zhang, Zhang, and Shen 2020 ; Zuo et al 2020 ), liver cancer ( Hann et al 2017 ), pancreatic cancer ( Terasawa et al 2019 ) and gastric cancer ( Shi et al 2017 ).…”

Section: Trans-renal Cell-free Dna In Oncologymentioning

confidence: 99%

Trans-Renal Cell-Free Tumor DNA for Urine-Based Liquid Biopsy of Cancer

et al. 2022

View full text Add to dashboard Cite

Cancer biomarkers are a promising tool for cancer detection, personalization of therapy, and monitoring of treatment response or recurrence. “Liquid biopsy” commonly refers to minimally invasive or non-invasive sampling of a bodily fluid (i.e., blood, urine, saliva) for detection of cancer biomarkers such as circulating tumor cells or cell-free tumor DNA (ctDNA). These methods offer a means to collect frequent tumor assessments without needing surgical biopsies. Despite much progress with blood-based liquid biopsy approaches, there are limitations—including the limited amount of blood that can be drawn from a person and challenges with collecting blood samples at frequent intervals to capture ctDNA biomarker kinetics. These limitations are important because ctDNA is present at extremely low levels in plasma and there is evidence that measuring ctDNA biomarker kinetics over time can be useful for clinical prediction. Additionally, blood-based assays require access to trained phlebotomists and often a trip to a healthcare facility. In contrast, urine is a body fluid that can be self-collected from a patient’s home, at frequent intervals, and mailed to a laboratory for analysis. Multiple reports indicate that fragments of ctDNA pass from the bloodstream through the kidney’s glomerular filtration system into the urine, where they are known as trans-renal ctDNA (TR-ctDNA). Accumulating studies indicate that the limitations of blood based ctDNA approaches for cancer can be overcome by measuring TR-ctDNA. Here, we review current knowledge about TR-ctDNA in urine as a cancer biomarker approach, and discuss its clinical potential and open questions in this research field.

show abstract

Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma

Cited by 17 publications

References 25 publications

Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review

Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review

Identification of RNA-splicing factor Lsm12 as a novel tumor-associated gene and a potent biomarker in Oral Squamous Cell Carcinoma (OSCC)

Trans-Renal Cell-Free Tumor DNA for Urine-Based Liquid Biopsy of Cancer

Contact Info

Product

Resources

About